Michelle Jacobson,
Michelle Jacobson
Institution: NULL
Email:
Nadia Coakley,
Nadia Coakley
Institution: NULL
Email:
Marcus Bernardini,
Marcus Bernardini
Institution: NULL
Email:
Kelly-Ann Branco,
Kelly-Ann Branco
Institution: NULL
Email:
Laurie Elit,
Laurie Elit
Institution: NULL
Email:
Sarah Ferguson,
Sarah Ferguson
Institution: NULL
Email:
Raymond Kim
Raymond Kim
Institution: NULL
Email:
Objective
The purpose of this guideline is to make recommendations regarding the care of women who harbour a pathogenic or likely pathogenic variant in BRCA1 and BRCA2
Methods
Draft recommendations were formulated based on evidence obtained through a systematic review of RCTs, comparative retrospective studies and guideline endorsement. Th...
1 month ago
Fu-Rong You,
Fu-Rong You
Institution: NULL
Email:
Hui-Jun Lai,
Hui-Jun Lai
Institution: NULL
Email:
Lan Yang,
Lan Yang
Institution: NULL
Email:
Hong-Wei Guo
Hong-Wei Guo
Institution: NULL
Email:
...
1 month ago
Jacek Gronwald,
Jacek Gronwald
Institution: NULL
Email:
Cezary Cybulski,
Cezary Cybulski
Institution: NULL
Email:
Tomasz Huzarski,
Tomasz Huzarski
Institution: NULL
Email:
Anna Jakubowska,
Anna Jakubowska
Institution: NULL
Email:
Tadeusz Debniak,
Tadeusz Debniak
Institution: NULL
Email:
Marcin Lener,
Marcin Lener
Institution: NULL
Email:
Steven A Narod,
Steven A Narod
Institution: NULL
Email:
Jan Lubinski
Jan Lubinski
Institution: NULL
Email:
BRCA1 and BRCA2 mutations contribute to both breast cancer and ovarian cancer worldwide. In Poland approximately 4% of patients with breast cancers and 10% of patients with ovarian cancer carry a mutation in BRCA1. The majority of mutations consist of three founder mutations. A rapid inexpensive test for these three mutations can be used to screen all Polish adults at a reasonable cost. In the reg...
1 month ago
Yue Yin Xia,
Yue Yin Xia
Institution: NULL
Email:
Joanne Kotsopoulos
Joanne Kotsopoulos
Institution: NULL
Email:
BRCA1 and BRCA2 mutation carriers face an elevated lifetime risk of developing ovarian cancer. Oral contraceptives have been shown to significantly decrease the risk of ovarian cancer by approximately 50% in this high-risk population. Changes in contraceptive formulations and patterns of use over time have introduced lower hormonal dosages, different steroid types and non-oral routes of administra...
1 month ago
Tina Kamani,
Tina Kamani
Institution: NULL
Email:
Parsa Charkhchi,
Parsa Charkhchi
Institution: NULL
Email:
Afshan Zahedi,
Afshan Zahedi
Institution: NULL
Email:
Mohammad R. Akbari
Mohammad R. Akbari
Institution: NULL
Email:
Non-medullary thyroid cancer (NMTC) is the most common type of thyroid cancer. With the increasing incidence of NMTC in recent years, the familial form of the disease has also become more common than previously reported, accounting for 5–15% of NMTC cases. Familial NMTC is further classified as non-syndromic and the less common syndromic FNMTC. Although syndromic NMTC has well-known genetic risk...
1 month ago